Nedocromil
Based on 1 Customer Validation
Nedocromil (FPL 59002) is a mast cell stabilizer and an inhibitor of IL-8 production. Nedocromil inhibits mast cell degranulation and collagen synthesis induced by activated mast cells, indirectly interfering with IL-1β signaling. Nedocromil reduces conjunctival eosinophil infiltration and improves the cutaneous manifestations of chronic graft-versus-host disease (including reducing fibrosis, loss of fat and hair follicles, and inflammatory infiltration). Nedocromil can be used in research on chronic graft-versus-host disease, asthma, and allergic conjunctivitis.
For research use only. We do not sell to patients.
- Purity : 98.19%
- CAS No.: 69049-73-6
- Formula: C19H17NO7
- Molecular Weight:371.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Biological Activity
Description
IC50 & Target
[1]|
IL-1β |
IL-8 |
In Vitro
Nedocromil sodium (up to 10-5 mol/L; 8 h) does not directly affect the chemotactic activity of IL-1β-stimulated human bronchial epithelial cell-conditioned media on human neutrophils[2].
Nedocromil sodium (10-5 mol/L; 4 h) significantly and dose-dependently reduces the IL-1β-induced release of immunoreactive IL-8 from cultured human bronchial epithelial cells without affecting constitutive release[2].
Nedocromil sodium (10-5 mol/L; 4 h) prevents the increased expression of IL-8 mRNA induced by IL-1β in cultured human bronchial epithelial cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human neutrophils and human bronchial epithelial cells
-
Concentration:up to 10^-5 mol/L
-
Incubation Time:8 h
-
Result:Did not significantly affect the chemotactic activity of epithelial cell-conditioned media at concentrations up to 10^-5 mol/L.
-
Cell Line:Human bronchial epithelial cells
-
Concentration:10^-5 mol/L (preincubation); 5 ng/mL (IL-1β)
-
Incubation Time:3-5 h (preincubation); 8 h (IL-1β stimulation)
-
Result:Reduced the release of immunoreactive IL-8 by >50% when added 3 to 5 hours before IL-1β.
Significantly reduced the release of immunoreactive IL-8 induced by IL-1β in a dose-dependent manner when preincubated for 4 hours.
Did not modify the constitutive release of IL-8 at concentrations up to 10^-5 mol/L.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-10 weeks, 20-25 g)[1]
-
Dosage:5 mg/mouse
-
Administration:i.p.; daily; 15 days
-
Result:Decreased the mean dermis/fat ratio to 1.5 compared to 4.0 in saline-treated cGVHD mice.
Normalized skin mast cell numbers from 1.71 to 2.95.
Increased peritoneal mast cell numbers to 1.45 compared to 0.25 in controls.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 69049-73-6
-
Appearance Solid
-
Molecular Weight 371.34
-
Formula C19H17NO7
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC(C2=CC3=C(N(CC)C(C(O)=O)=CC3=O)C(CCC)=C2O1)=O)O
-
Synonyms
FPL 59002
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
In Vitro:
DMSO : 16.67 mg/mL (44.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6929 mL | 13.4647 mL | 26.9295 mL | 67.3237 mL |
| 5 mM | 0.5386 mL | 2.6929 mL | 5.3859 mL | 13.4647 mL | |
| 10 mM | 0.2693 mL | 1.3465 mL | 2.6929 mL | 6.7324 mL | |
| 15 mM | 0.1795 mL | 0.8976 mL | 1.7953 mL | 4.4882 mL | |
| 20 mM | 0.1346 mL | 0.6732 mL | 1.3465 mL | 3.3662 mL | |
| 25 mM | 0.1077 mL | 0.5386 mL | 1.0772 mL | 2.6929 mL | |
| 30 mM | 0.0898 mL | 0.4488 mL | 0.8976 mL | 2.2441 mL | |
| 40 mM | 0.0673 mL | 0.3366 mL | 0.6732 mL | 1.6831 mL |
Keywords
- Nedocromil
- 69049-73-6
- FPL 59002
- FPL59002
- FPL-59002
- Interleukin Related
- IL-1β-induced IL-8 production
- human bronchial epithelial cells
- asthma
- mast cell stabilizer
- skin mast cell numbers
- mast cell degranulation
- IL-8 mRNA
- allergic conjunctivitis
- chronic graft-versus-host disease
- human neutrophils
- Inhibitor
- inhibitor
- inhibit